Growth Hormone Treatment of Early Growth Failure in Toddlers with Turner Syndrome: A Randomized, Controlled, Multicenter Trial
Open Access
- 1 September 2007
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (9), 3406-3416
- https://doi.org/10.1210/jc.2006-2874
Abstract
Context: Typically, growth failure in Turner syndrome (TS) begins prenatally, and height sd score (SDS) declines progressively from birth. Objective: This study aimed to determine whether GH treatment initiated before 4 yr of age in girls with TS could prevent subsequent growth failure. Secondary objectives were to identify factors associated with treatment response, to determine whether outcome could be predicted by a regression model using these factors, and to assess the safety of GH treatment in this young cohort. Design: This study was a prospective, randomized, controlled, open-label, multicenter clinical trial (Toddler Turner Study, August 1999 to August 2003). Setting: The study was conducted at 11 U.S. pediatric endocrine centers. Subjects: Eighty-eight girls with TS, aged 9 months to 4 yr, were enrolled. Interventions: Interventions comprised recombinant GH (50 μg/kg·d; n = 45) or no treatment (n = 43) for 2 yr. Main Outcome Measure: The main outcome measure was baseline-to-2-yr change in height SDS. Results: Short stature was evident at baseline (mean length/height SDS = −1.6 ± 1.0 at mean age 24.0 ± 12.1 months). Mean height SDS increased in the GH group from −1.4 ± 1.0 to −0.3 ± 1.1 (1.1 SDS gain), whereas it decreased in the control group from −1.8 ± 1.1 to −2.2 ± 1.2 (0.5 SDS decline), resulting in a 2-yr between-group difference of 1.6 ± 0.6 SDS (P < 0.0001). The baseline variable that correlated most strongly with 2-yr height gain was the difference between mid-parental height SDS and subjects’ height SDS (r = 0.32; P = 0.04). Although attained height SDS at 2 yr could be predicted with good accuracy using baseline variables alone (R2 = 0.81; P < 0.0001), prediction of 2-yr change in height SDS required inclusion of initial treatment response data (4-month or 1-yr height velocity) in the model (R2 = 0.54; P < 0.0001). No new or unexpected safety signals associated with GH treatment were detected. Conclusion: Early GH treatment can correct growth failure and normalize height in infants and toddlers with TS.Keywords
This publication has 35 references indexed in Scilit:
- Catch-Up Growth: Testing the Hypothesis of Delayed Growth Plate Senescence in HumansThe Journal of Pediatrics, 2005
- Impact of growth plate senescence on catch-up growth and epiphyseal fusionPediatric Nephrology, 2005
- Circulating concentrations of insulin-like growth factor I and risk of breast cancerThe Lancet, 1998
- Growth hormone therapy of Turner's syndrome: Beneficial effect on adult heightThe Journal of Pediatrics, 1998
- Reference values for height, height velocity and weight in Turner's SyndromeActa Paediatrica, 1997
- Study of final height in Turner's syndrome: ethnic and genetic influencesActa Paediatrica, 1994
- Turner syndrome: Final height, glucose tolerance, bone density and psychosocial status in 25 adult patientsEuropean Journal of Pediatrics, 1994
- Growth in Infancy and Childhood in Girls with Turner's SyndromeActa Paediatrica, 1991
- Chromosome abnormalities found among 34910 newborn children: results from a 13-year incidence study in rhus, DenmarkHuman Genetics, 1991
- Growth curve for girls with Turner syndrome.Archives of Disease in Childhood, 1985